Starting Antihypertensive Drug Treatment With Combination Therapy
Zhen-Yu Zhang,Yu-Ling Yu,Kei Asayama,Tine W. Hansen,Gladys E. Maestre,Jan A. Staessen
DOI: https://doi.org/10.1161/hypertensionaha.120.12858
IF: 9.8968
2021-02-11
Hypertension
Abstract:The 2018 European Society of Cardiology/European Society of Hypertension 1 and the 2020 International Society of Hypertension 2 guidelines for the management of hypertension proposed that initial combination therapy with 2 antihypertensive agents in a single-pill combination (SPC) is preferred in most patients in need of blood pressure (BP) lowering treatment and should replace the long-standing concept of starting treatment with a single agent, rotating through antihypertensive drug classes, and next moving towards combining drug classes. By moving SPCs forward as the initial BP-lowering strategy, the European 1 and International 2 Societies of Hypertension Guideline Committees overlooked several principles in hypertension management: (1) understanding the pathophysiology of hypertension; (2) prioritizing evidence from randomized clinical trials above observational studies and expert opinion; and (3) giving consideration to the cost-effectiveness of antihypertensive drug treatment and the sustainability of health care. This article addresses these points. Sources of information included (1) guidelines issued by European, 1 , 3 , 4 American, 5–7 International, 2 , 8 , 9 and British 10–12 Expert Committees, published between 1999 8 and 2020, 2 summarized in Table S1 in the Data Supplement ; (2) a PubMed search ran on May 5, 2020, without limitations with as search terms in the abstract or title "hypertension" combined with "fixed combination" OR "hypertension" combined with "single" and "costs"; (3) the placebo-controlled trials of antihypertensive drug treatment, as identified from the reference lists of 5 systematic literature reviews, 13–17 of which 2 were published by the Blood Pressure Lowering Trialists' Collaboration 14 , 16 ; (4) 3 randomized controlled trials of usual versus intensive BP control 18–20 ; and (5) the retail costs of antihypertensive drugs on the Belgian market ( https://www.bcfi.be ). Tailoring Antihypertensive Treatment In the early 1970s, Laragh's group coined the terms low-renin, normal-renin, and high-renin hypertension by relating plasma renin activity to the daily sodium excretion. 21 Under normal conditions, plasma renin activity increases with sodium restriction but decreases with higher BP. 21 Although an imperfect generalization, low-renin hypertension is characterized by volume expansion and its high-renin counterpart by increased peripheral resistance, 22 , 23 and are indications to start BP-lowering treatment with a diuretic as opposed to an inhibitor of the renin-angiotensin system or vasodilator. 24 The activity of the renin system decreases with advancing age 22 and is lower in Blacks compared with Whites. 25–27 These pathophysiological principles explain why guidelines, with the exception of the 2018 European 1 and the 2020 International 2 guidelines recommend to start antihypertensive drug treatment with ACE (angiotensin-converting enzyme) inhibitors or ARBs below age 55 and with thiazide diuretics (TDs) or dihydropyridine CCBs (calcium-channel blockers) in older patients and in Blacks across the adult age range. Isolated systolic hypertension, which in its initial course is not associated with increased peripheral resistance, but is caused by stiffening of the large arteries 28 is an indication for TDs 29 or CCBs. 30 , 31 The 2020 International Society of Hypertension guideline -Abstract Truncated-
peripheral vascular disease